Allurion Technologies (NYSE:ALUR) vs. Alphatec (NASDAQ:ATEC) Head-To-Head Contrast

Alphatec (NASDAQ:ATEC) and Allurion Technologies (NYSE:ALUR) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, analyst recommendations, profitability, earnings and valuation.

Earnings and Valuation

This table compares Alphatec and Allurion Technologies”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alphatec	$572.74 million	2.28	-$186.64 million	($1.28)	-7.18
Allurion Technologies	$34.75 million	0.81	-$80.61 million	($0.48)	-0.91

Allurion Technologies has lower revenue, but higher earnings than Alphatec. Alphatec is trading at a lower price-to-earnings ratio than Allurion Technologies, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

66.3% of Alphatec shares are held by institutional investors. Comparatively, 21.4% of Allurion Technologies shares are held by institutional investors. 22.8% of Alphatec shares are held by insiders. Comparatively, 22.4% of Allurion Technologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Alphatec and Allurion Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Alphatec	-31.06%	-541.39%	-22.99%
Allurion Technologies	-71.24%	N/A	-56.75%

Analyst Ratings

This is a breakdown of current ratings for Alphatec and Allurion Technologies, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alphatec	0	1	8	0	2.89
Allurion Technologies	0	1	3	1	3.00

Alphatec presently has a consensus price target of $17.11, suggesting a potential upside of 86.19%. Allurion Technologies has a consensus price target of $2.88, suggesting a potential upside of 561.22%. Given Allurion Technologies’ stronger consensus rating and higher possible upside, analysts plainly believe Allurion Technologies is more favorable than Alphatec.

Risk & Volatility

Alphatec has a beta of 1.38, meaning that its stock price is 38% more volatile than the S&P 500. Comparatively, Allurion Technologies has a beta of -0.56, meaning that its stock price is 156% less volatile than the S&P 500.

Summary

Alphatec beats Allurion Technologies on 8 of the 15 factors compared between the two stocks.

About Alphatec

Alphatec Holdings, Inc., a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems. It also provides split-blade retractors; Sigma-ALIF Access System, a procedure-specific access system; spinal implants and fixation systems comprising NanoTec surface modifications, Calibrate PSX, and Invictus, as well as various standalone implants for height restoration and stabilization. In addition, the company provides biologics comprising 3D ProFuse Osteoconductive Bioscaffold for ease of handling and better endplate-to-endplate contact; AlphaGRAFT Demineralized Bone Matrix (DBM) comprising demineralized human tissues; AlphaGRAFT DBM Fibers comprising demineralized fibers; AlphaGRAFT Cellular Bone Matrix (CBM), a growth factor-enriched cellular bone matrix; AlphaGRAFT CBM that is delivered in granular, fiber, or structural form; BioCORE Moldable Bioactive Graft, a synthetic mineral-collagen composite matrix that can be molded to fit the bone defect; and Amnioshield Amniotic Tissue Barrier, an allograft for spinal surgical barrier applications. The company sells its products through a network of independent sales agents and direct sales representatives. Alphatec Holdings, Inc. was founded in 1990 and is headquartered in Carlsbad, California.

About Allurion Technologies

Allurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon), as well as offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite. Allurion Technologies Inc. is headquartered in Natick, Massachusetts.